Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.
Results from the ADACTA trial, have resulted in a modest to substantial increase in prescribing of RoActemra by 43 percent to 60 percent of surveyed rheumatologists across the EU5.... Learn More
Join us live on December 10, 2013... Learn More
View Webinar schedule and archive
See which reports have been searched on the most.
Global Biosimilars Pathways and Clinical Development Activity. Where Are the Biosimilars Hotspots?
This new infographic from BioTrends Research Group’s Biosimilars Advisory Service: Global Pipelines, Regulatory Pathways and Key Stakeholder Perspectives highlights global market activity for the dynamic and complex biosimilars industry.
December 5, 2013
The Approval of the First Biosimilar Monoclonal Antibody in Europe Has Major Implications for 2014 and Beyond
Surveyed Oncologists Indicate that the Use of Biomarker Testing is Increasing Rapidly in Non-Small-Cell Lung Cancer in China and South Korea
Approval of Stelara for Psoriatic Arthritis and for Self-Administration is Likely to Help the Drug’s Uptake in the Psoriasis Market
Key Findings from Treatment Algorithms: Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a complex autoimmune condition characterized by chronic and progressive joint... Read More
Epilepsy (Event Driven)
Last Updated 6 December 2013 With approximately 5.3 million patients diagnosed in the seven major... Read More
Acute Coronary Syndrome (Event Driven)
Last Updated 5 December 2013Acute coronary syndrome (ACS)—an umbrella term that encompasses acute... Read More